Assessment of Drug-Drug Interaction between Warfarin and Aprepitant and Its Effects on PT-INR of Patients Receiving Anticancer Chemotherapy.

Author: HisakaAkihiro, OhnoYoshiyuki, SuzukiHiroshi, TakakiJunpei, YamadaMaiko, YamaguchiRyo

Overview

Aprepitant can increase the levels of a key enzyme that breaks down warfarin, a blood thinner. This can reduce the effectiveness of warfarin and increase the risk of blood clots. The study found that the levels of warfarin in the blood can fluctuate significantly for up to two weeks after aprepitant is started. Therefore, it is important to closely monitor the level of warfarin in the blood for at least two weeks after starting aprepitant.

Paper Details　

Original Abstract of the Article :

Aprepitant is a known inducer of CYP2C9, the main warfarin-metabolizing enzyme. Consequently, co-administration of these two drugs may result in reduction of the anticoagulation activity of warfarin. However, the nature and degree of time-dependent changes in prothrombin time international normalize...See full text at original site

Dr.Camel's Paper Summary Blog

Drug-Drug Interaction Between Warfarin and Aprepitant

The world of pharmaceuticals is filled with complex interactions, and managing medication regimens can be challenging. This study, like a camel navigating a winding path through a desert of medications, explores the potential drug-drug interaction between warfarin, a blood thinner, and aprepitant, an anti-nausea medication often used in cancer treatment.

The study retrospectively examined the effects of aprepitant on warfarin's anticoagulation activity, analyzing changes in prothrombin time international normalized ratio (PT-INR) in patients receiving anticancer chemotherapy. The researchers aimed to understand the time-dependent changes in PT-INR after co-administration of these medications, providing valuable insights into the management of patients receiving both drugs.

Aprepitant Can Fluctuate Warfarin's Anticoagulation Activity

The study revealed that aprepitant can significantly fluctuate warfarin's anticoagulation activity, requiring careful monitoring of PT-INR to ensure patient safety. The findings emphasize the importance of close monitoring during the first two weeks after aprepitant administration to adjust warfarin dosage as needed.

Dr. Camel's Conclusion

This study provides crucial information about the potential drug-drug interaction between warfarin and aprepitant. The findings highlight the need for vigilant monitoring of PT-INR in patients receiving both medications to ensure safe and effective anticoagulation therapy.